A unique new flexible and stretchable device, worn against the skin and capable of producing electrical energy by transforming the compounds present in sweat, was recently developed and patented by CNRS researchers from l’Université Grenoble Alpes and UC San Diego (USA). This cell is already capable of continuously lighting an LED, opening new avenues for the development of wearable electronics powered by autonomous and environmentally friendly biodevices.
This research was published in Advanced Functional Materials on September 25, 2019.
The potential uses for wearable electronic devices continue to increase, especially for medical and athletic monitoring. Such devices require the development of a reliable and efficient energy source that can easily be integrated into the human body. Using “biofuels” present in human organic liquids has long been a promising avenue.
Scientists from the Département de chimie moléculaire (CNRS/Université Grenoble Alpes), who specialize in bioelectrochemistry, decided to collaborate with an American team from UC San Diego, who are experts in nanomachines, biosensors, and nanobioelectronics. Together they developed a flexible conductive material consisting of carbon nanotubes, crosslinked polymers, and enzymes joined by stretchable connectors that are directly printed onto the material through screen-printing1.
The biofuel cell, which follows deformations in the skin, produces electrical energy through the reduction of oxygen and the oxidation of the lactate present in perspiration.
Once applied to the arm, it uses a voltage booster to continuously power an LED. It is relatively simple and inexpensive to produce, with the primary cost being the production of the enzymes that transform the compounds found in sweat. The researchers are now seeking to amplify the voltage provided by the biofuel cell in order to power larger portable devices.
The Latest on: Biofuel cell
via Google News
The Latest on: Biofuel cell
- Renewal Bio Acquires Breakthrough Stem Cell Technology With Applications in Infertility and Longevityon August 3, 2022 at 7:00 am
Renewal Bio, a newly formed biotechnology company focused on infertility and longevity, today announced it has acquired an exclusive license from Yeda Research and Development Co Ltd, the commercial ...
- 2seventy bio to Participate in Upcoming Investor Conferenceson August 3, 2022 at 4:30 am
(Nasdaq: TSVT) announced today that members of the management team will participate in the following upcoming investor conferences: 2022 Wedbush PacGrow Healthcare Conference, “A View to a Kill (er ...
- Orca Bio announces the Precision-T phase 3 study open and enrolling patients across US transplant centerson August 3, 2022 at 12:45 am
T, its pivotal phase 3 study, is open, enrolling and treating 174 leukemia patients at more than 20 clinical trial sites. Precision-T is a randomized, open-label multi-center study that is evaluating ...
- Generation Bio to Present at the 2022 Wedbush PacGrow Healthcare Conferenceon August 2, 2022 at 1:17 pm
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a panel at ...
- Researchers reprogram stem cells to uncover new genetic signatures of age-related AMDon August 2, 2022 at 7:34 am
Researchers are closer to better diagnosing and treating age-related macular degeneration (AMD) after discovering new genetic signatures of the disease by reprogramming stem cells to generate ...
- Orca Bio Announces the Precision-T Phase 3 Study is Open and Enrolling Patients at Transplant Centers Across the U.S.on August 2, 2022 at 6:00 am
Orca Bio today announced Precision-T, its pivotal Phase 3 study, is open, enrolling and treating patients at clinical trial sites.
- Adicet Bio to Present at Upcoming Investor Conferenceson August 1, 2022 at 1:11 pm
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, ...
- Vor Bio to Participate in Upcoming Investor Conferenceson August 1, 2022 at 5:00 am
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: BTIG Biotechnology Conference 2022 ...
- Modifi Bio comes up with a new technology to combat cancer cells with DNA modificationon July 28, 2022 at 10:46 pm
Modifi Biosciences announced today that the journal Science has published a critical study validating the company's novel oncology platform based on new classes of molecules that exploit ...
- Mission Bio launches new cancer assayon July 28, 2022 at 8:25 am
Mission Bio has announced the first assay capable of determining measurable residual disease in cancer down to the level of individual cells.
via Bing News